Drug Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Allergies
Collegium Pharmaceutical Provides Update on Development of its Nasal Inhaled Steroid for Allergic Rhinitis
August 31st, 2007
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company with a focus on respiratory and CNS disorders, announced an update on the development of its most advanced prescription product candidate for the treatment of allergic rhinitis. Collegium previously announced that it had acquired, from Muro Pharmaceutical, Inc., all rights to its Tri-Nasal(R) (triamcinolone acetonide, USP) Nasal Spray, including the product's approved NDA and the right to market the product. Triamcinolone acetonide is the same active ingredient found in Nasacort(R) AQ (Aventis) which had 2006 US sales of approximately $350 million according to IMS Health. Tri-Nasal(R) received FDA approval as a once-daily,...
Source: Drug Week (2007-08-31)
|
